PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast

Go online to PeerView.com/CWT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in nephrology discuss emerging evidence for improving outcomes and preventing chronic kidney disease (CKD) progression using nonsteroidal mineralocorticoid receptor antagonists. Upon completion of this activity, participants should be better able to: Apply current guidance consistent with the latest recommendations for screening, diagnosis, and treatment of patients with or at risk of developing CKD, Describe the interrelationships among CKD and other common cardiometabolic comorbidities, Evaluate the role and clinical potential of novel nonsteroidal mineralocorticoid receptor antagonists in providing renoprotection and preventing disease progression in patients diagnosed with CKD.

Go online to PeerView.com/HBK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live web broadcast, a multidisciplinary panel explores the latest data for HIF-PH inhibitors and examines their efficacy and safety in treating anemia in patients with chronic kidney disease (CKD). The panel also shares evidence-based strategies and describes new models of care for managing patients with CKD-associated anemia, as well as offers practical insight on how clinical pharmacists may take an active role in improving clinical outcomes in patients with CKD. Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Differentiate the mechanisms of action of current and emerging treatments for anemia associated with CKD, Recognize the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia associated with CKD in both nondialysis- and dialysis-dependent patients, Apply evidence-based strategies to effectively coordinate with the healthcare team to identify patients with anemia-associated CKD who would likely derive benefit from treatment with a HIF-PH inhibitor.

Go online to PeerView.com/BFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in cardiovascular diseases and heart failure (HF) research presents a patient case to explore current evidence-based recommendations for diagnosing iron deficiency (ID) to encourage timely and appropriate treatment to improve outcomes in patients with HF. Upon completion of this activity, participants should be better able to: Describe the prevalence of ID in patients with HF and its impact on patient outcomes and quality of life, Interpret laboratory results for diagnosing and monitoring iron status in patients with HF, Apply current clinical guidelines and clinical trial results for iron therapies to improve outcomes in patients with ID and HF.

Go online to PeerView.com/YAS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert nephrologist discusses hyperkalemia in patients with hemodialysis-dependent chronic kidney disease (CKD) and explores the role of potassium binders in the treatment of hyperkalemia. Upon completion of this activity, participants will be able to: Differentiate currently available agents for the management of hyperkalemia according to their mechanisms of action, Apply current guidelines and best-available evidence to the management of hyperkalemia in patients with hemodialysis-dependent CKD.

Go online to PeerView.com/DFZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CME activity, based on a recent live webcast, leading experts examine the vital role of primary care physicians in the management of patients who have or are at risk of DR and DME and offer practical insight on current screening recommendations, risk factor management, and novel treatment options to improve outcomes. Upon completion of this activity, participants should be better able to: Reconcile current guidance offered in evidence-based treatment recommendations regarding screening, diagnosis, and treatment of patients with suspected DR with or without DME, Counsel patients with DR with or without DME about the effects a timely diagnosis and initiation of appropriate treatment options can have on outcomes, Implement strategies that overcome barriers to ensure the timely and appropriate referral to ophthalmologic specialists who can utilize treatment regimens that have been shown to improve outcomes and/or encourage regression of DR, Discuss newer treatment options in a manner that overcomes patient-related barriers and encourages them to seek care from ophthalmologic specialists.

Go online to PeerView.com/EVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this case-based activity, an expert ophthalmologist and expert endocrinologist discuss the importance of diagnosing patients with diabetic retinopathy with or without diabetic macular edema early and how individualizing treatment improves outcomes. After participating in this activity, the learner will demonstrate the ability to: Describe current evidence-based recommendations for screening, diagnosis, and treatment of patients with suspected DR with or without DME, Facilitate timely diagnosis and treatment initiation, as appropriate, for patients with DR with or without DME, Incorporate strategies that overcome barriers to ensure timely and appropriate referral to ophthalmologic specialists who can utilize treatment regimens that have been shown to improve outcomes and/or encourage regression of DR in patients with diabetes.

Go online to PeerView.com/RBT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in cardiometabolic health discusses the role and ability of SGLT2 inhibitors to improve renal outcomes in patients with T2DM and/or CKD. Upon completion of this activity, participants should be better able to: Outline the mechanism(s) of action and clinical potential of newer options in glucose-lowering therapy that have been shown to improve renal outcomes in patients with T2DM, Evaluate the clinical efficacy and safety of newer options in glucose-lowering therapy in patients with T2DM and/or CKD, Integrate newer glucose-lowering therapies to improve the management of patients with T2DM and/or CKD based on the latest clinical evidence.

Go online to PeerView.com/SVU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) describes shared decision-making strategies to individualize treatment and reduce cardiovascular risks in patients with T2DM using GLP-1 receptor agonists (GLP-1 RAs). Upon completion of this activity, participants should be better able to: Review the role of, current guidance, and approved indications for GLP-1 RAs in the management of T2DM, Describe the difference between primary and secondary prevention of cardiovascular events and the mechanism(s) proposed for GLP-1 RAs that may reduce cardiovascular risks in patients with T2DM, Evaluate the benefits and risks of GLP-1 RAs based on results from recent clinical trials, especially in terms of primary and secondary cardiovascular prevention, Integrate GLP-1 RAs, as appropriate and using shared decision-making, into the care of patients with T2DM.

Go online to PeerView.com/MVV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, a panel of experts offers insight into best practices regarding the treatment of anemia associated with chronic kidney disease (CKD) and emphasizes that the success of employing current (and future) treatments falls on the members of the interdisciplinary nephrology care team. Foundational guidance is combined with a discussion of real cases to further highlight new developments in the management of anemia associated with CKD and provide practical guidance on the integration of such advances. Upon completion of this activity, participants will be able to: Describe the prevalence, clinical impact, and pathogenesis of anemia in CKD, Identify benefits and limitations associated with current management approaches to anemia in CKD, Recognize the mechanism of action of emerging hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in the management of anemia in CKD, Assess safety and efficacy data supporting HIF-PH inhibitor use in patients with anemia in CKD, Employ strategies to treat anemia in CKD in accordance with current evidence, expert recommendations, and individual patient needs.

Go online to PeerView.com/KMS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in chronic kidney disease (CKD) discusses anemia in CKD and explores the potential role of HIF-PH inhibitors in the treatment of this condition. Upon completion of this activity, participants will be able to: Identify the epidemiology, pathology, and burden of anemia associated with CKD, Discuss limitations of the current model of treatment for anemia associated with CKD, Differentiate the mechanisms of action of current and emerging treatments for anemia associated with CKD, Recognize the benefits and limitations of current and emerging agents to treat anemia in CKD.